anti-α4β7 monoclonal antibody

Anti-α4β7 monoclonal antibodies are a class of targeted biologic therapies designed to selectively inhibit the α4β7 integrin heterodimer, a cell-surface glycoprotein primarily expressed on gut-homing T and B lymphocytes. By binding to α4β7, these antibodies block its interaction with mucosal addressin cell adhesion molecule 1 (MAdCAM-1), which is highly expressed on the vascular endothelium of the gastrointestinal tract. This blockade prevents the trafficking and adhesion of inflammatory leukocytes into the intestinal mucosa, thereby reducing gut-specific inflammation. The most prominent approved therapeutic in this class is vedolizumab (Entyvio), which is widely used for the treatment of moderate-to-severe ulcerative colitis and Crohn's disease. Other candidates in development or historically evaluated include abrilumab (AMG 181) and the half-life extended subcutaneous antibody SPY001.

Other names

anti-alpha4beta7 mAbanti-alpha-4beta7 mAbanti-alpha 4beta7 mAbanti-alpha4beta7 monoclonal antibodyanti-alpha-4beta7 monoclonal antibodyanti-alpha 4beta7 monoclonal antibodyanti-α4β7 mAb